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Background: The purpose of the research is to study the histopathology and expression of survivin, estrogen and
progesterone receptors (ER/PR) in the endometrium of patients with dysfunctional uterine bleeding (DUB) treated
with radiofrequency endometrial ablation (REA).
Methods: A total of 98 DUB patients were enrolled in this case–control study. Among them, 66 underwent REA
treatment and 32 optioned for hormone therapy as the control group. Immunohistochemical analysis for survivin,
ER and PR expression was carried out on endometrial tissue samples collected before and 6 to 7 months after
treatment for both groups.
Results: Both hormone and REA treatment ameliorated menstrual bleeding of DUB patients, with the latter
showing a significantly higher effective rate. Endometrial surface tissue was replaced by fibrosis tissue in the REA
treatment group. REA treatment also significantly reduced the expression of survivin, ER, and PR. Endometrial
surface tissues collected from the hormone-treated control group neither showed any apparent morphological
alteration nor in the expression of those receptors.
Conclusions: REA treatment changed endometrial surface tissue type from gland rich to gland poor, and
significantly decreased the expression of survivin, ER, and PR. This may be an important contributing mechanism for
the long-term curative effect and prevention of DUB recurrence.
Keywords: Dysfunctional uterine bleeding (DUB), Radiofrequency endometrial ablation (REA), Survivin, Estrogen
receptor (ER), Progesterone receptor (PR)Background
Dysfunctional uterine bleeding (DUB) is a common
gynecological disease, affecting 19% of women of child-
bearing age and perimenopausal women [1,2]. The treat-
ment options usually include drugs or surgery, both of
which have significant disadvantages such as recurrence of
the symptoms and dysfunctional uterus [2-5]. How to
improve the efficacy of minimally-invasive surgery has
become a widely-recognized concern [6,7]. Radiofrequency
endometrial ablation (REA) is a minimally-invasive tech-
nique recently developed in gynecology [8-12]. After* Correspondence: ygpwylll@hotmail.com
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reproduction in any medium, provided the ordelivering a radiofrequency source into the uterine cavity
a thermal effect (approximately 60-85°C) is produced
which causes thermocoagulation, denaturation, and necro-
sis of endometrial tissue, as well as peripheral vascular
thrombosis, which stops the bleeding [12].
There were histopathological studies on the treatment
of menorrhagia using thermocoagulation endometrial
ablation [2,6]. However, study of the histopathology and
the expression for survivin, estrogen receptors (ER), and
progesterone receptors (PR) in the endometrium of
DUB patients after REA is lacking. Therefore, the
current study was aimed to evaluate the histopathology
and expression of survivin, ER, and PR in the endomet-
rium of DUB patients, using conventional histological. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of changes of these molecules and the potential long-





This was a prospective study. The patient inclusion cri-
teria were: age > 30 years without the desire of fertility, a
clear diagnosis of DUB, pictorial blood loss assessment
chart (PBAC) [13] >100, and benign endometrial prolif-
erative lesions without cellular atypia confirmed by cur-
ettage pathology during the period of persistent
abnormal uterine bleeding; and those who provided
informed consent for treatment and research. The study
was approved by the Institutional Review Board. The
procedures were in accordance with the ethical stan-
dards of the responsible local or national committee on
human experimentation and with the Helsinki Declar-
ation (1975, revised 1983, World Medical Association
Declaration of Helsinki). Patients who did not complete
the follow-up or who had malignant gynecological can-
cer or other serious internal illness (including severe
heart diseases, liver cirrhosis, and cerebral thrombosis)
were excluded from the study. A total of 98 DUB
patients were consecutively enrolled from June 2007 to
June 2010. None of them had endometrial carcinoma.
The REA group consisted of 66 DUB patients, all Han
Chinese, with an average age of 42.5 years (range 33–
50 years), and a pre-treatment PBAC score of
182.5 ± 67.5 (time from treatment to endometrial curet-
tage ranged from 6.5 to 12 months, with an average
9.1 ± 3.0 months). The treatment effect was defined as
either a curative effect (post-treatment PBAC score <80),
significant effect (PBAC score of 80–100), or treatment
failure (PBAC score > 100). The rate of treatment effect-
iveness was defined as the sum of the curative effect and
significant effect rates.
The control group was enrolled by 1:2 and consisted
of 32 DUB patients who met the study eligibility criteria
and opted for hormone therapy. Their average age was
43.5 years (range 32–48 years) and their pre-treatment
PBAC score was 177.0 ± 67.8. Each patient began with
progesterone-norethindrone (Shanghai Xinyikangjie
Pharmaceutical Inc., Shanghai, China) at 5.0 mg every
8 h for 2–3 days. After the bleeding stopped, the dosage
was reduced by one-third every 3 days until the daily
maintenance dose of approximately 2.5-5.0 mg was
reached. Patients then continued the treatment to
21 days post-hemostasis. If the symptoms of DUB re-
curred months later, hormone therapy was repeated. If
the symptoms of DUB exacerbated, other treatment,
such as hysterectomy, was considered.Endometrial specimens were collected by curettage be-
fore treatment and post-treatment (6 to 7 months) for
both the REA treated and the hormone-treated control
groups.
REA treatment
The Kangpu XVC-III gynecological RF therapy device
(Xi’an Vize Electronic Technology Co. Ltd., Xi’an, China)
was used for REA with the following technical para-
meters: 220 v ± 10%, 50 Hz ± 2%, P ≤ 60 w, I <2 A, 600
KHz ± 15%, power setting in the 40 w.
REA procedure According to preoperative hysteroscopy
data and guided by the color Doppler ultrasound, the
coagulator was delivered to the bottom of the uterine
cavity. After the coagulator was turned on, the active
surface contacted the uterus membrane. From top to
bottom, left to right, the coagulator was moved inside
the uterine cavity in two circles, with the speed of 1 cm
every 6–12 s. When moved to the left or right, the dis-
tance was the width of a coagulator. Movement was
made between the anterior and posterior wall of the
uterus three times, and the left and right side wall once
(the whole procedure generally took 10 to 15 min to
complete).
Histopathology and immunohistochemical assay
Reagents and materials include: (1) conventional histo-
logical reagents including paraffin embedding materials,
H&E staining solutions, and so on; and (2) for immuno-
histochemistry, mouse monoclonal antibodies against
human survivin, ER, and PR (NeoMarkers Products,
USA) and universal streptomycin avidin-peroxidase
hypersensitive (SP) staining kit (Santa Cruz Products,
Germany).
Histology and immunostaining
Endometrial biopsy samples were embedded with paraf-
fin, and serial sections at 4 μm thickness were prepared.
Some sections underwent regular H&E staining. Other
sections were processed for immunostaining for survi-
vin, ER, and PR, as described in details below.
Sections were deparaffinized, rehydrated, and under-
went antigen retrieval process using ethylenediaminete-
traacetic acid (EDTA) solution. After washing in 0.1 M
PBS, sections were incubated overnight in primary anti-
bodies for survivin, ER or PR at 4°C. The sections were
then incubated successively in biotinylated secondary
antibody (reagent C) for 10 min; streptomycin-
peroxidase solution (reagent D) for 10 min; and followed
by freshly prepared DAB/H2O2 solution from the stain-
ing kit for 2–10 min. After a further wash in PBS, the
sections were counterstained with hematoxylin, dehy-
drated, and mounted with neutral gum for microscopic
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included using known positive sections as the positive
control, and omission of primary antibodies or their re-
placement with PBS as the negative control.
Assessment of immunohistochemical assay
(1) Survivin immunohistochemical staining scoring
criteria (ISSC): Survivin expression was primarily
localized in the cytoplasm of endometrial epithelial
cells and occasionally in the nucleus. Brown-yellow
granules in the cytoplasm and/or nuclei indicated
positive (positive cells). Ten randomly selected fields
were examined under light microscope for each
section. The scoring was based on the following two
scales: A. The intensity of staining: 0 points for no
staining, 1 point for weak staining, 2 points for
moderate staining, and 3 points for intense staining;
B: The percentage of positive cells in all cells
counted: 0 point if positive cell is ≤ 5%, 1 point =
6-25%, 2 points = 26-50%, and 3 points if ≥ 51%. The
combination of these two scales for each section
was used as the score for survivin immunostaining
(ranged between 0–9 in total). This score was
considered as the level of survivin expression in the
study, and the mean and standard deviation were
calculated for each group.
(2) ER and PR ISSC: ER and PR expression were mainly
localized in the nucleus of endometrial epithelial
cells and stromal cells. Brown-yellow granules in the
nucleus and/or cytoplasm indicated positive
(positive cells). Ten randomly chosen fields were
examined under light microscope for each section.
The percentage of positive cells was quantified by
counting 100 cells in total for each field. The mean
and standard deviation of the percentage of positive
cells were calculated for all fields examined.
Statistics
The Student t-test was used for continuous data, and
the χ2 test was used for categorical data. Commercially
available software was used to perform the tests (SPSS
13.0). Statistical significance was defined as P <0.05.Table 1 The changes of the pathology type before and after
Histopathological types C
Before treatm
Fibrous connective tissue and granulation tissue 0 (0.0%)
Some endometrial glands and granulation tissue 0 (0.0%)
Proliferative endometrium 8 (25.0%)
Simple hyperplasia 14 (43.8%)
Complex hyperplasia 10 (31.2%)
Statistics is Fisher probabilistic method (compared with before treatment). n, numbResults
The effect on DUB of the hormone-treated control and
the REA-treated groups
There was no statistical difference between REA and the
control group on geographic distribution, ethnicity, age,
pre-treatment PBAC scores, and time from treatment to
curettage (P > 0.05). In the control group, the PBAC
score decreased from 177.0 ± 67.8 at baseline to
120 ± 70.2 at 8.5 months (8.5 ± 2.5 months) post-treat-
ment, which was statistically significant (P < 0.05). The
total effective rate of DUB was 56.3% (18/32 cases- there
were 14 patients whose symptoms of DUB recurred
months later, exacerbated after another course of hor-
mone therapy and eventually undertook hysterectomy).
In the REA group, the PBAC score decreased from
182.5 ± 67.5 at baseline to 56.7 ±22.0 at 9.1 months
(9.1 ± 3.0 months) post-treatment, which showed a
greater significant difference (P < 0.01). In addition, the
reduction of the PBAC scores from baseline to post
treatment follow-up was significantly higher in the REA
group (125.8 ± 44.5) than in control group (57.2 ± 37.5)
(P < 0.01). Furthermore, the total effective rate of the
REA group reached 95.5% (63/66 cases), which was also
higher than that in the control group (95.5% vs. 56.3%,
P < 0.05). These results indicate that REA had better
treatment effects than the hormone therapy.
Endometrial histopathology before and 6 to 7 months
after REA
Tables 1 and 2 list changes of the pathology type before
and after treatment in both groups. Prior to treatment,
DUB patients in the REA group showed benign prolif-
erative endometrial glands, some of which were irregu-
larly enlarged and closely arranged into a ‘back to back’
shape (Figure 1A). After 6 to 7 months of REA, most
endometrial tissues were shown to be replaced by granu-
lation tissue, and only small amounts of glands remained
which were small in size, and surrounded by fibrosis tis-
sue (Figure 1B).
χ2 test showed that there was no significant difference
in the endometrial pathological types between the two
groups before any treatment (P > 0.05). In the control
group there was no significant difference in thetreatment in control groups
ontrol groups n (%) Statistics
ent After treatment χ2 P
0 (0.0%) - -
0 (0.0%) - -
15 (46.9%) 3.326 >0.05
12 (37.5%) 0.259 >0.05
5 (15.6%) 2.177 >0.05
er of cases.
Table 2 The changes of the pathology type before and after treatment in REA groups
Histopathological types REA group n (%) Statistics
Before treatment After treatment χ2 P
Fibrous connective tissue and granulation tissue 0 (0.0%) 20 (30.3%) 23.030 <0.01
Some endometrial glands and granulation tissue 0 (0.0%) 27 (40.9%) 32.832 <0.01
Proliferative endometrium 16 (24.2%) 13 (19.7%) 0.461 >0.05
Simple hyperplasia 30 (45.5% 4 (6.1%) 25.611 <0.01
Complex hyperplasia 20 (30.3%) 2 (3.0%) 17.220 <0.01
Statistics is Fisher probabilistic method (compared with before treatment).
n, number of cases; REA, radiofrequency endometrial ablation.
Figure 1 Endometrial pathology and survivin, ER, and PR
expression before and 6 to 7 months after REA treatment in
DUB patients with complex endometrial hyperplasia. (A) Before
REA, the endometrium showed complex hyperplasia, ‘back to back’
glandular hyperplasia, leather bag shape glandular enlargement. (B)
Six to seven months after REA, glandular tissue became fibrous
tissue with scarce glands and blood vessels in endometrial
curettage. (C) Before REA, the expression of survivin (strong positive).
(D) Six months after REA, the expression of surviving showed weak
positive. (E) Before REA, the expression of ER (strong positive). (F) Six
months after REA, the expression of ER showed weak positive. (G)
Before REA, the expression of PR (strong positive). (H) Six months
after REA, the expression of PR showed weak positive. DUB,
dysfunctional uterine bleeding; ER, Estrogen receptors; PR,
Progesterone receptor; REA, Radiofrequency endometrial ablation.
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ment (P > 0.05). In contrast, there was a significant dif-
ference between the pathological types before and after
treatment in the REA group (P < 0.01). In addition, REA
treated group showed a significant difference in the
pathological types when compared with the control
group (P < 0.01).
Expression of survivin, ER, and PR expression before and
6 to 7 months after treatment in the control group
The analysis showed that prior to the hormone treat-
ment, the average expression for all three molecules
(survivin, ER, and PR) were higher in endometrial tissues
with complex hyperplasia than those with simple hyper-
plasia or proliferative endometrium, but the differences
were not significant (P > 0.05). The mean levels of three
molecules slightly decreased after the hormone treat-
ment, but again the differences were not significant
(P > 0.05) (Table 3).
Expression of survivin, ER, and PR before and 6 to 7
months after treatment in REA treatment group
Before REA, the expression of survivin was strong in the
cytoplasm of glandular cells (Figure 1C). After REA (6 to
7 months follow-up), it was weak (Figure 1D) (Figure 1
E, F, G, H, Table 4).
Before treatment, the expression levels of survivin, ER,
and PR were not significantly different between the REA
and control groups (P > 0.05). After treatment, there was
a significant reduction in the expression of these three
molecules in the REA group (P < 0.05). The differences
in the levels of survivin, ER, and PR expression before
and after treatment were also greater in the REA group
than those in the control group (P < 0.05).
Complications associated with RF procedure and
treatment/prevention measures
Abdominal pain occurred within 24 h after treatment in
30.3% (20/66) of RF subjects. Endometrial coagulation
necrosis can stimulate uterine cramps and contractions
that may result in abdominal pain, usually occurring
within 12 h of treatment. Patients were treated for
Table 3 Endometrial tissues survivin, ER, and PR expression before and after treatment in the control group
Pathology before treatment n Before treatment (mean± SD) After treatment (mean± SD)
Survivin scores ER (%) PR (%) Survivin scores ER (%) PR (%)
Proliferative endometrium 8 5.5 ± 1.2 53.3 ± 18.1 40.6 ± 27.3 5.7 ± 1.8 55.6 ± 30.1 51.8 ± 37.0
Simple hyperplasia 14 6.1 ± 1.8 58.1 ± 16.3 44.7 ± 262 5.9 ± 1.6 57.6 ± 34.3 50.7 ± 30.1
Complex hyperplasia 10 8.5 ± 2.0 86.2 ± 36.2 85.3 ± 21.5 6.7 ± 2.3 82.7 ± 32.1 77.1 ± 36.4
The comparisons were between before and after treatment.
n, number of cases; ER, estrogen receptor; PR, progesterone receptor.
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The incidence of post-treatment intrauterine adhe-
sions was 7.6% (5/66); no severe adhesions presented. At
1 and 3 months post-operation, the uterine cavity was
examined for adhesions using a No. 4 cervical dilator. In
young women, an intrauterine device (IUD) was inserted
as a means to separate the adhesions, or the adhesions
were separated under hysteroscopy. Infection control
was provided with the prescription of routine antibiotics
for 1 to 2 weeks after treatment; no severe endometritis
or pelvic inflammatory disease occurred among the
patients.
Discussion
The endometrium of patients with anovulatory DUB is
continuously stimulated by estrogen without the antag-
onism of progesterone, resulting in various degrees of
proliferative changes followed by repeated bleeding [1].
Thermalcoagulation effects of REA can directly inacti-
vate the estrogen and progesterone receptors in the le-
sion. However, the literature on the expression of
estrogen and progesterone receptors and survivin in the
repaired tissues at 6 to7 months after treatment is lack-
ing. This might be important in understanding whether
REA can provide long-term effects beyond temporary
hemostasis.
The action of REA treatment on DUB
In medical physics, sinusoidal alternating current with a
frequency greater than 100 kHz is called radio frequency
(RF). As RF can create a thermal effect (approximately
60-85°C) in biological tissues at an approximate depth of
treatment of 5–7 mm, a coagulator can cause the follow-
ing changes in endometrial tissue to achieve the purposeTable 4 Endometrial tissues survivin, ER, and PR expression b
Pathology before treatment n Before treatment (me
Survivin scores ER (%)
Proliferative endometrium 16 5.7 ± 1.7 53.3 ± 18.3
Simple hyperplasia 30 7.2 ± 1.7 51.4 ± 15.7
Complex hyperplasia 20 8.1 ± 2.3 79.9 ± 20.4
The comparisons were between before and after treatment.
aP <0.05.
n, number of cases; ER, estrogen receptor; PR, progesterone receptor; REA, radiofreqof DUB treatment: (1) direct thermal coagulation and
necrosis or apoptosis of the endometrial functional layer
and the basal cell layer; (2) peripheral intravascular co-
agulation around the lesion and bleeding cessation; and
(3) gradual replacement of endometrial tissues by fibrous
connective tissue that do not ablate periodically. The
histopathology data from this study showed decreases in
simple hyperplasia and complex hyperplasia, and
increases in gland-free fibrous connective tissue and
granulation tissue with fewer endometrial glands in the
endometrium following REA treatment.
The effects of REA on survivin, ER, and PR and potential
mechanism for long-term effectiveness on DUB
The survivin gene is the only one in the inhibitor of
apoptosis proteins (IAP) family that was found to be
related to both apoptosis and the regulation of the cell
cycle. Studies have shown that survivin has partial or
complete low expression in the normal endometrium,
which may be due to the active proliferation of endo-
metrial cells [14,15]. The expression of PR and ER in
endometrial cells of patients with anovulatory DUB was
found higher than normal, and was positively correlated
with the degree of endometrial proliferation [16,17].
The histopathologic results of the study showed that
REA can directly cause the coagulation, necrosis, col-
lapse, occlusion, and disappearance of glandular lumen
in the endometrium. The endometrium was gradually
replaced by fibrous granulation tissue that does not ab-
late periodically, which may lead to the reduction of
menstrual flow or amenorrhea. Immunohistochemical
data of the study showed that the expression levels of
survivin, ER, and PR in fibrous granulation tissue after
REA treatment were significantly reduced, and were also
significantly lower than those in the hormone treatedefore and after treatment in the REA group
an± SD) After treatment (mean± SD)
PR (%) Survivin scores ER (%) PR (%)
45.9 ± 22.3 2.5 ± 1.7a 23.8 ± 10.4a 11.3 ± 7.5a
54.2 ± 25.7 1.8 ± 0.9a 18.9 ± 14.4a 26.9 ± 11.3a
86.7 ± 31.6 2.9 ± 0.3a 18.3 ± 12.1a 21.4 ± 6.8a
uency endometrial ablation.
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expression of survivin, ER, and PR from the scattered
glands in the fibrous endometrium remained low, which
is likely to result in a diminished response to estrogen
and progesterone stimulation. The decreased expression
of the receptors would suggest a suppressed binding abil-
ity to estrogen and progesterone. Whether the suggestion
is another mechanism for the DUB recurrence-prevention
and long-term effectiveness of REA treatment needs
further studies.
Conclusions
REA treatment changed endometrial surface tissue type
from gland rich to gland poor, and significantly decreased
the expression of survivin, ER, and PR. This may be an
important contributing mechanism for the long-term
curative effect and prevention of DUB recurrence.
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